UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000019666
Receipt number R000022725
Scientific Title Genomic Analysis of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
Date of disclosure of the study information 2015/11/09
Last modified on 2019/11/14 18:14:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer

Acronym

Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer

Scientific Title

Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer

Scientific Title:Acronym

Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer

Region

Japan


Condition

Condition

Small Cell Lung Cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer

Basic objectives2

Others

Basic objectives -Others

Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer

Trial characteristics_1

Exploratory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

genomic analysis of circulating tumor cells in patients
with small cell lung cancer by collecting blood samples at pre-, and post- treatment.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

patients newly diagnosed as having SCLC and starting chemotherapy or chemoradiotherapy

Key exclusion criteria

<20 years old

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yamaoka Toshimitsu

Organization

Showa University

Division name

institute of molecular oncology

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo

TEL

03-3784-8146

Email

yamaoka.t@med.showa-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yamaoka Toshimitsu

Organization

Showa University

Division name

institute of molecular oncology

Zip code


Address

1-5-8 Hatanodai, Shinagawa-ku, Tokyo

TEL

03-3784-8146

Homepage URL


Email

yamaoka.t@med.showa-u.ac.jp


Sponsor or person

Institute

Yamaoka Toshimitsu

Institute

Department

Personal name



Funding Source

Organization

Showa University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor

Center for Antibody and Vaccine Therapy,
Research Hospital, The Institute of Medicine,
University of Tokyo

Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2015 Year 11 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2015 Year 11 Month 09 Day

Date of IRB

2015 Year 10 Month 28 Day

Anticipated trial start date

2015 Year 11 Month 09 Day

Last follow-up date

2019 Year 11 Month 14 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

patients with small cell lung cancer met the inclusion criteria and were prospectively enrolled between November 2015 and September 2018.


Management information

Registered date

2015 Year 11 Month 06 Day

Last modified on

2019 Year 11 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022725


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name